What does Xencor, Inc. do?
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis…
What is Xencor, Inc.'s P/E and P/B ratio?
Xencor, Inc. has a P/E ratio of -12.0 and a P/B ratio of 3.82.
What is Xencor, Inc.'s debt-to-equity ratio?
Xencor, Inc. has a debt-to-equity ratio of 0.34.
How much does Xencor, Inc. owe compared with what it owns?
Xencor, Inc. owes $0.31 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Xencor, Inc.'s Positivity rank?
Xencor, Inc. is ranked #5,381 of 6,774 companies globally and #2,917 of 4,000 in United States on PositoAI, with a Positivity Score of 17,569.
Does Xencor, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Xencor, Inc..
Where can I read the latest news about Xencor, Inc.?
Recent headlines about Xencor, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Xencor, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Xencor, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.